199 related articles for article (PubMed ID: 35543293)
1. A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.
Cobb P; Niederwieser D; Cohen S; Hamm C; Burmester G; Seo N; Lehto SG; Hanes V
Immunotherapy; 2022 Jun; 14(9):727-740. PubMed ID: 35543293
[TBL] [Abstract][Full Text] [Related]
2. A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar.
Reinisch W; Cohen S; Ramchandani M; Khraishi M; Liu J; Chow V; Franklin J; Colombel JF
Adv Ther; 2022 Jan; 39(1):44-57. PubMed ID: 34757601
[TBL] [Abstract][Full Text] [Related]
3. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.
Burmester G; Chien D; Chow V; Gessner M; Pan J; Cohen S
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1003-1014. PubMed ID: 32627420
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.
Burmester G; Drescher E; Hrycaj P; Chien D; Pan Z; Cohen S
Clin Rheumatol; 2020 Nov; 39(11):3341-3352. PubMed ID: 32876780
[TBL] [Abstract][Full Text] [Related]
6. Non-clinical similarity of biosimilar ABP 798 with rituximab reference product.
McBride HJ; Jassem S; Chow V; Kanakaraj P; Lebrec H; Kuhns S; Ferbas J; Wong M; Thway TM
Biologicals; 2021 Jul; 72():42-53. PubMed ID: 34303595
[TBL] [Abstract][Full Text] [Related]
7. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
[TBL] [Abstract][Full Text] [Related]
8. Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product.
Seo N; Huang Z; Kuhns S; Sweet H; Cao S; Wikström M; Liu J
Biologicals; 2020 Nov; 68():79-91. PubMed ID: 32888776
[TBL] [Abstract][Full Text] [Related]
9. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
10. Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases.
Jurczak W; Cohen S; Illidge TM; Silva AD; Amersdorffer J
Future Oncol; 2019 Dec; 15(36):4223-4234. PubMed ID: 31718287
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
12. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
Thomas M; Thatcher N; Goldschmidt J; Ohe Y; McBride HJ; Hanes V
Immunotherapy; 2019 Oct; 11(15):1337-1351. PubMed ID: 31556762
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
Rioufol C; Salles G
Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product.
Niederwieser D; Hamm C; Cobb P; Mo M; Forsyth C; Tucci A; Hanes V; Delwail V; Hajek R; Chien D
Target Oncol; 2020 Oct; 15(5):599-611. PubMed ID: 33044684
[TBL] [Abstract][Full Text] [Related]
15. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
[TBL] [Abstract][Full Text] [Related]
16. Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
Genovese MC; Sanchez-Burson J; Oh M; Balazs E; Neal J; Everding A; Hala T; Wojciechowski R; Fanjiang G; Cohen S
Arthritis Res Ther; 2020 Mar; 22(1):60. PubMed ID: 32216829
[TBL] [Abstract][Full Text] [Related]
17. CT-P10 (Truxima™): A Rituximab Biosimilar.
Deeks ED
BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
19. A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.
Choi D; Lee S; Kim S; Yoon S
Clin Drug Investig; 2022 Apr; 42(4):285-300. PubMed ID: 35325438
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
